Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients
Yıl: 2020 Cilt: 8 Sayı: 3 Sayfa Aralığı: 129 - 134 Metin Dili: İngilizce DOI: 10.25002/tji.2020.1347 İndeks Tarihi: 28-12-2021
Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients
Öz: Introduction: The outbreak of novel coronavirus COVID-19 infections that started in China late 2019 has spread rapidly and cases have been recorded worldwide. So, in this study, we sought clarification of the clinical characteristics and importance of changing the lymphocyte group, antibodies, CD markers, and interleukin-6 in the serum of COVID-19 patients, which may help to clarify the pathogen and develop new biomarkers. Material and Methods: Venous blood samples had been accumulated from patients before taking any medications. Sera had been separated and saved at (-20°C) until analysis. Serum anti-SARS-CoV-2 immunoglobulins (IgG, IgA, and IgM) were determined in plasma samples using enzyme-linked immunosorbent assays (ELISA) and Serum IL-6 was assessed. Results: Median IgM (p=0.001), IgG (p<0.0001), and IgA (p<0.001), were decreased in patients comparing with control the control group. There is a significant decrease in CD3+and CD4+cells compared to healthy individuals in patients infected with COVID-19 (p<0.0001). CD19+cell count decreased in COVID-19 patients compared to that of the control group (p<0.0001). After calculating CD4+ /CD8+cell ratio decreased in COVID-19 patients (p<0.0001). However, CD56+cells were found to be increased (p<0.0001). Conclusions: IgM, IgG, IgA levels and CD19+ , CD4+cells, CD4+ /CD8+cell ratio were found to be decreased whereas CD8+ , CD3+ , CD4+cells were detected to be increased in COVID-19 patients compared to those of healthy controls.
Anahtar Kelime: COVID-19 Hastalarında İmmünoglobülinler, CD4+/CD8+ T Lenfosit Oranları ve Interlökin-6 Düzeyinin Değerlendirilmesi
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Jalil, AT. COVID-19 most affected age groups and lethality in Europe. Global J Public Health Med 2020;2:179–84.
- 2. National Health Commission of the People’s Republic of China. Update on the novel coronavirus pneumonia outbreak (Feb 16, 2020). http://www.nhc.gov.cn/xcs/ yqtb/202002/18546da875d74445bb537ab014e7a1c6.shtml
- 3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
- 4. Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immun 2004;136:95–103.
- 5. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. New Eng J Med 2020;382:1787–99.
- 6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.
- 7. Li T, Qiu Z, Zhang L, Han Y, He W, Liu Z, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis 2004;189:648–51.
- 8. Malik YS, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M, et al. Emerging novel coronavirus (2019-nCoV) –current scenario, evolutionary perspective based on genome analysis and recent developments. Veterinary Quarterly 2020;40:68–76.
- 9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. New Eng J Med 2020;382:1708–20.
- 10. World Health Organization. Laboratory Testing for Coronavirus Disease 2019(COVID-19) in Suspected Human Cases: Interim Guidance, 2 March 2020 World Health Organization, 2020. https://apps.who.int/iris/handle/10665/331329
- 11. Jawhara S. Could Intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci 2020;21:2272.
- 12. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol 2017;29:491–8.
- 13. Zhang J, Liu J, Li N, Liu Y, Ye R, Qin X, Zheng R. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. medRxiv 2020.
- 14. Gunther N, Hoffmann GW. Qualitative dynamics of a network model of regulation of the immune system: a rationale for the IgM to IgG switch. J Theor Biol 1982;94:815–55.
- 15. Li G, Chen X, Xu A. Profile of specific antibodies to the SARSassociated coronavirus. New Engl J Med 2003;349:508–9.
- 16. Jung MC, and Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43–50.
- 17. Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis 2020;102437.
- 18. Bai, Tao and Tu, Shengjin and Wei, Yuan and Xiao, Li and Jin, Yan and Zhang, Lei and Song, Jun and Liu, Weihua and Zhu, Qingjing and Yang, Ling and Chen, Hua and Hou, Xiaohua, Clinical and Laboratory Factors Predicting the Prognosis of Patients with COVID-19: An Analysis of 127 Patients in Wuhan, China (2/26/2020). Available at SSRN: https://ssrn.com/ abstract=3546118.
- 19. Lim L, Hamblin MR. Can the Vielight X-Plus be a Therapeutic Intervention for COVID-19 Infection? uietMIND Foundation 2020. https://www.quietmindfdn.org/ uploads/2/0/4/9/20494094/vielight-x-plus-for-covid-study-v2. pdf
- 20. Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Molec Dis 2020;83:102437.
- 21. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6(IL-6)level in critically ill COVID-19 patients. Clin Infect Dis 2020;ciaa449.
- 22. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Médecine et Maladies Infectieuses 2020;50:382–3.
- 23. Arnaldez FI, O’Day SJ, Drake CG, Fox BA, Fu B, Urba WJ, et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer 2020;8:e000930.
- 24. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. MedRxiv 2020.
| APA | Mahmood Saleh M, Jalil A, Abdulwahid Abdulkareem R, Suleiman A (2020). Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. , 129 - 134. 10.25002/tji.2020.1347 |
| Chicago | Mahmood Saleh Marwan,Jalil Abduladheem Turki,Abdulwahid Abdulkareem Rafid,Suleiman Ahmed Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. (2020): 129 - 134. 10.25002/tji.2020.1347 |
| MLA | Mahmood Saleh Marwan,Jalil Abduladheem Turki,Abdulwahid Abdulkareem Rafid,Suleiman Ahmed Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. , 2020, ss.129 - 134. 10.25002/tji.2020.1347 |
| AMA | Mahmood Saleh M,Jalil A,Abdulwahid Abdulkareem R,Suleiman A Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. . 2020; 129 - 134. 10.25002/tji.2020.1347 |
| Vancouver | Mahmood Saleh M,Jalil A,Abdulwahid Abdulkareem R,Suleiman A Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. . 2020; 129 - 134. 10.25002/tji.2020.1347 |
| IEEE | Mahmood Saleh M,Jalil A,Abdulwahid Abdulkareem R,Suleiman A "Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients." , ss.129 - 134, 2020. 10.25002/tji.2020.1347 |
| ISNAD | Mahmood Saleh, Marwan vd. "Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients". (2020), 129-134. https://doi.org/10.25002/tji.2020.1347 |
| APA | Mahmood Saleh M, Jalil A, Abdulwahid Abdulkareem R, Suleiman A (2020). Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. Turkish Journal of Immunology, 8(3), 129 - 134. 10.25002/tji.2020.1347 |
| Chicago | Mahmood Saleh Marwan,Jalil Abduladheem Turki,Abdulwahid Abdulkareem Rafid,Suleiman Ahmed Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. Turkish Journal of Immunology 8, no.3 (2020): 129 - 134. 10.25002/tji.2020.1347 |
| MLA | Mahmood Saleh Marwan,Jalil Abduladheem Turki,Abdulwahid Abdulkareem Rafid,Suleiman Ahmed Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. Turkish Journal of Immunology, vol.8, no.3, 2020, ss.129 - 134. 10.25002/tji.2020.1347 |
| AMA | Mahmood Saleh M,Jalil A,Abdulwahid Abdulkareem R,Suleiman A Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. Turkish Journal of Immunology. 2020; 8(3): 129 - 134. 10.25002/tji.2020.1347 |
| Vancouver | Mahmood Saleh M,Jalil A,Abdulwahid Abdulkareem R,Suleiman A Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients. Turkish Journal of Immunology. 2020; 8(3): 129 - 134. 10.25002/tji.2020.1347 |
| IEEE | Mahmood Saleh M,Jalil A,Abdulwahid Abdulkareem R,Suleiman A "Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients." Turkish Journal of Immunology, 8, ss.129 - 134, 2020. 10.25002/tji.2020.1347 |
| ISNAD | Mahmood Saleh, Marwan vd. "Evaluation of Immunoglobulins, CD4/CD8 T Lymphocyte Ratio and Interleukin-6 in COVID-19 Patients". Turkish Journal of Immunology 8/3 (2020), 129-134. https://doi.org/10.25002/tji.2020.1347 |
